We’d love to hear your feedback on this activity. It helps us to continually improve our products.
The randomized phase III PERSEUS trial (NCT03710603) investigated daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) compared with VRd and lenalidomide alone in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). Daratumumab, a CD38 monoclonal antibody, is currently approved for use in several treatment regimens aimed at both transplant-eligible and non-transplant-eligible NDMM. In this […]
We’re looking forward to the upcoming ASH Annual Meeting & Exposition 2023 which is taking place in San Diego between 9 – 12 December.
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in this disease. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study […]
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Abstract 4553: Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (00:25-00:57) Abstract 569: A Dexamethasone Sparing-Regimen […]
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the updated efficacy analysis from the phase III MAIA study presented at the recent ASH 2022 congress. There were also some additional post-hoc efficacy analyses on key subgroups (Abstracts 4553 and 3245). Abstract 3245: Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible […]
Get the latest clinical insights from touchONCOLOGY